Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
VVOS Transcript
Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript
Unknown4-15
The earnings call reveals significant financial challenges: a 50.5% increase in operating expenses, a widened net loss, and substantial liabilities, which overshadow the 17% gross profit increase. The Q&A section highlights revenue drops due to provider absences and an unclear path to cash flow positivity. While there are growth prospects with new models and partnerships, the immediate financial health and guidance issues, coupled with increased debt, suggest a negative stock price reaction.
Vivos Therapeutics, Inc. (VVOS) Q3 2025 Earnings Call Transcript
Unknown11-19
The earnings call presents a mixed picture. While there is a significant revenue growth and expansion plans, concerns remain about cash flow and profitability due to ongoing net losses and high expenses. The Q&A section reveals optimism for future growth but lacks specific timelines for breakeven, which could worry investors. The slight decrease in gross margin and the substantial net loss further contribute to a neutral sentiment. Without market cap data, the impact on stock price is uncertain, but the lack of clear guidance tempers the positive elements.
Vivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call Transcript
Unknown8-22
The earnings call reveals several concerns: a 6% revenue decline, increased operating losses, high acquisition costs, and cash flow challenges. Despite potential long-term benefits from acquisitions and strategic alliances, the immediate financial strain and reliance on debt raise red flags. No positive shareholder return plan was discussed, and the Q&A section did not clarify management's responses. Without a market cap, the stock's volatility is uncertain, but the financial issues suggest a negative short-term outlook.
Earnings call transcript: Vivos Therapeutics reports Q1 2025 earnings, stock rises
Unknown5-15
The earnings call reveals mixed financial performance, with declining total revenue and gross margins, and an increase in operating loss. While there are positive developments, such as the SCN acquisition and potential revenue growth, the company's financial health is concerning, with significant cash burn and increased operational expenses. The Q&A section highlighted management's vague responses regarding financial impact, raising concerns. Given these factors, the stock price is likely to react negatively in the short term, with a potential decline between -2% to -8%.
VVOS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
